Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Dendrite Charts. Click Here for more Dendrite Charts.](/p.php?pid=staticchart&s=N%5EDRTE&p=8&t=15)
Dendrite International, Inc. (NASDAQ:DRTE), a leading provider of
pharmaceutical industry solutions, today announced that the Company and
its chairman and chief executive officer, John Bailye, have been honored
at the tenth annual New Jersey Technology Council (NJTC) Gala Awards.
Mr. Bailye won the John H. Martinson Technology Supporter Award, while
Dendrite was inducted into NJTC’s prestigious
Hall of Fame. The awards, which are given each year to recognize and
celebrate New Jersey technology companies and their leaders for business
accomplishments in technological innovation, were presented on November
16, 2006 at the New Jersey Performing Arts Center in Newark, NJ.
Mr. Bailye was honored for his significant commitment to the support and
advancement of technology in New Jersey. As an entrepreneur who moved
Dendrite from Australia to the US in 1986, Mr. Bailye has continually
demonstrated an innovative spirit and uncompromising drive to deliver
leading pharmaceutical-specific solutions to its client base. Mr. Bailye’s
other accolades have included the Ernst & Young’s
New Jersey Software and Technology Entrepreneur of the Year, Business
Review Weekly’s top 20 influential Australians
in the United States, and the Golden Door Award from the New Jersey
International Institute, which recognizes those who have come to the
United States and achieved commercial success.
Today, as a result of Mr. Bailye’s visionary
leadership and deep pharmaceutical expertise, Dendrite serves clients in
more than 50 countries, including the world’s
top 20 pharmaceutical companies.
“Since Dendrite’s
inception 20 years ago, John has been the embodiment of innovation and
visionary leadership,” said Joe Ripp,
president and COO of Dendrite. “Recognition
by the NJTC is an honor both for John and Dendrite and we’re
proud to have Dendrite inducted into the NJTC Hall of Fame.”
About Dendrite
Founded in 1986, Dendrite International (NASDAQ:DRTE) enables sales,
marketing, clinical and compliance solutions for the global
pharmaceutical industry. The company has clients in more than 50
countries and includes the world's top 20 pharmaceutical companies. For
more information, please visit www.dendrite.com.
About NJTC
The New Jersey Technology Council (NJTC) provides business support,
networking opportunities, information, advocacy and recognition of
technology companies and their leaders. Founded in 1996, NJTC's more
than 1,200 member companies work together to support their own
enterprises while advancing New Jersey's status as a leading technology
center in the United States. For more information, please visit www.njtc.org.
Note: Dendrite is a registered trademark of Dendrite International, Inc.
This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook," "guidance,"
and similar statements or variations. Such forward-looking statements
are based on our current expectations, estimates, assumptions and
projections and involve significant risks and uncertainties, including
risks which may result from our dependence on the pharmaceutical
industry; fluctuations in quarterly revenues due to lengthy sales and
implementation cycles for certain of our solutions; our fixed expenses
in relation to fluctuating revenues and variations in customers' budget
cycles; dependence on certain major customers; changes in demand for our
products and services attributable to any weakness experienced in the
economy or mergers, acquisitions and consolidations in the
pharmaceutical industry; successful and timely development and
introduction of new products and versions; rapid technological changes;
increased competition; international operations; integrating the
entities we acquire; our ability to effectively manage our growth; the
protection of our proprietary technology; our ability to compete in the
Internet-related products and services market; the continued demand for
Internet-related products and services; the ability of our third party
vendors to respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than anticipated
results from strategic relationships; dependence of data solutions on
strategic relationships; events which may affect the U.S. and world
economies; and catastrophic events which could negatively affect our
information technology infrastructure. Other important factors that
should be reviewed and carefully considered are included in the
company's 10-K, 10-Qs, and other reports filed with the SEC. Actual
results may differ materially. The company assumes no obligation for
updating any such forward-looking statements to reflect actual results,
changes in assumptions or other changes affecting such forward-looking
statements.
Dendrite International, Inc. (NASDAQ:DRTE), a leading provider of
pharmaceutical industry solutions, today announced that the Company
and its chairman and chief executive officer, John Bailye, have been
honored at the tenth annual New Jersey Technology Council (NJTC) Gala
Awards. Mr. Bailye won the John H. Martinson Technology Supporter
Award, while Dendrite was inducted into NJTC's prestigious Hall of
Fame. The awards, which are given each year to recognize and celebrate
New Jersey technology companies and their leaders for business
accomplishments in technological innovation, were presented on
November 16, 2006 at the New Jersey Performing Arts Center in Newark,
NJ.
Mr. Bailye was honored for his significant commitment to the
support and advancement of technology in New Jersey. As an
entrepreneur who moved Dendrite from Australia to the US in 1986, Mr.
Bailye has continually demonstrated an innovative spirit and
uncompromising drive to deliver leading pharmaceutical-specific
solutions to its client base. Mr. Bailye's other accolades have
included the Ernst & Young's New Jersey Software and Technology
Entrepreneur of the Year, Business Review Weekly's top 20 influential
Australians in the United States, and the Golden Door Award from the
New Jersey International Institute, which recognizes those who have
come to the United States and achieved commercial success.
Today, as a result of Mr. Bailye's visionary leadership and deep
pharmaceutical expertise, Dendrite serves clients in more than 50
countries, including the world's top 20 pharmaceutical companies.
"Since Dendrite's inception 20 years ago, John has been the
embodiment of innovation and visionary leadership," said Joe Ripp,
president and COO of Dendrite. "Recognition by the NJTC is an honor
both for John and Dendrite and we're proud to have Dendrite inducted
into the NJTC Hall of Fame."
About Dendrite
Founded in 1986, Dendrite International (NASDAQ:DRTE) enables
sales, marketing, clinical and compliance solutions for the global
pharmaceutical industry. The company has clients in more than 50
countries and includes the world's top 20 pharmaceutical companies.
For more information, please visit www.dendrite.com.
About NJTC
The New Jersey Technology Council (NJTC) provides business
support, networking opportunities, information, advocacy and
recognition of technology companies and their leaders. Founded in
1996, NJTC's more than 1,200 member companies work together to support
their own enterprises while advancing New Jersey's status as a leading
technology center in the United States. For more information, please
visit www.njtc.org.
Note: Dendrite is a registered trademark of Dendrite
International, Inc.
This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our solutions;
our fixed expenses in relation to fluctuating revenues and variations
in customers' budget cycles; dependence on certain major customers;
changes in demand for our products and services attributable to any
weakness experienced in the economy or mergers, acquisitions and
consolidations in the pharmaceutical industry; successful and timely
development and introduction of new products and versions; rapid
technological changes; increased competition; international
operations; integrating the entities we acquire; our ability to
effectively manage our growth; the protection of our proprietary
technology; our ability to compete in the Internet-related products
and services market; the continued demand for Internet-related
products and services; the ability of our third party vendors to
respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than
anticipated results from strategic relationships; dependence of data
solutions on strategic relationships; events which may affect the U.S.
and world economies; and catastrophic events which could negatively
affect our information technology infrastructure. Other important
factors that should be reviewed and carefully considered are included
in the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to reflect
actual results, changes in assumptions or other changes affecting such
forward-looking statements.